Compare BLTE & GSAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLTE | GSAT |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 7.4B |
| IPO Year | 2021 | 2006 |
| Metric | BLTE | GSAT |
|---|---|---|
| Price | $158.49 | $82.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $198.00 | $70.50 |
| AVG Volume (30 Days) | 117.4K | ★ 2.0M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $112,660,000.00 |
| Revenue This Year | N/A | $10.31 |
| Revenue Next Year | $492.11 | $15.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $56.68 | $17.24 |
| 52 Week High | $200.00 | $82.10 |
| Indicator | BLTE | GSAT |
|---|---|---|
| Relative Strength Index (RSI) | 43.63 | 68.62 |
| Support Level | $157.63 | $56.44 |
| Resistance Level | $161.28 | N/A |
| Average True Range (ATR) | 6.26 | 1.18 |
| MACD | -1.15 | -0.24 |
| Stochastic Oscillator | 17.27 | 94.90 |
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
Globalstar Inc is a telecommunications company that derives revenue from the provision of mobile satellite services. Mobile satellite services, including voice and data communications services to retail, business, and governmental customers, as well as wholesale satellite capacity services. The company provides communications services such as two-way voice and data transmission. In addition, one-way data transmission is also offered. Both services are offered using mobile or fixed devices. The company is the owner of satellite assets. It has one reportable segment: the MSS business. The company generates the vast majority of its revenue within the United States.